Roche Pharma Day 2019

London, 16 September 2019
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss of or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

All mentioned trademarks are legally protected.
Roche Pharma Day / Late Stage Pipeline Event 2019

Welcome

Karl Mahler | Head of Investor Relations
Agenda

Welcome
Karl Mahler, Head of Investor Relations

Pharma strategy, portfolio planning, productivity and new technologies
Bill Anderson, CEO Pharma

Market opportunities, pricing & access
Teresa Graham, Head Global Product Strategy Pharma

Late stage pipeline Oncology
Sandra Horning, Chief Medical Officer and Head Global Product Development

Late stage pipeline Neuroscience
Paulo Fontoura, Head of Neuroscience Clinical Development

Afternoon: Break-out sessions (will be repeated once)

Immunology & Infectious diseases
Cristin Hubbard / Zafar Hakim

Late stage pipeline Ophthalmology
Atul Dandekar / Sascha Fauser

Digitalisation & Personalized healthcare
Bryn Roberts

Buffet reception
“Firsts” under Sandra Horning’s leadership

• **New endpoints:**
  - *pCR endpoint:* Perjeta + Herceptin first FDA and EMA approval primarily on pCR
  - *MRD (Minimal Residual Disease):* Data convincing health authorities to use as early endpoint

• **Transformative treatments:**
  - First in areas of high unmet need – Ph 3 Huntington’s, Ocrevus PPMS
  - Hemlibra – adoption of innovative approaches enabling pediatric label on adult data

• **Innovation first:**
  - Leaders in BTD, 26 since inception – 60% based on Ph 1/2 data
  - Data to filing timelines cut by ~40% by end 2019
Strongly enriched portfolio under Sandra’s leadership

Late stage projects by therapeutic area

Late stage projects by new molecular entity

+148%

+62%

2010  YTD 2019

2010  YTD 2019
Outlook positive as launched products and pipeline gain momentum

*Where do we stand right now?*

**Today we will provide an up-date on:**

- Priorities for the next years to come
- Growth outlook for newly launched drugs
- Development status for late stage pipeline assets
- ‘Deep dive’ into Neuroscience and Digitalisation
Doing now what patients need next